|1.||Jalan, Rajiv: 7 articles (11/2014 - 07/2009)|
|2.||Hazen, Stanley L: 4 articles (03/2012 - 07/2005)|
|3.||Takács, Tamás: 4 articles (11/2011 - 07/2008)|
|4.||Dósa, Sándor: 4 articles (11/2011 - 07/2008)|
|5.||Rakonczay, Zoltán: 4 articles (11/2011 - 07/2008)|
|6.||Biczó, György: 4 articles (11/2011 - 07/2008)|
|7.||Iványi, Béla: 4 articles (11/2011 - 07/2008)|
|8.||Hegyi, Péter: 4 articles (11/2011 - 07/2008)|
|9.||Ando, Akira: 4 articles (03/2011 - 11/2003)|
|10.||Ito, Seiji: 4 articles (03/2011 - 11/2003)|
04/01/1981 - "These results suggest that reduction of plasma ornithine may be beneficial in gyrate atrophy patients and that the high ornithine concentrations characteristic of this disorder play some role in the pathophysiology."
12/05/1980 - "Gyrate atrophy of the choroid and retina: improved visual function following reduction of plasma ornithine by diet."
10/01/2013 - "Gyrate atrophy of the choroid and retina diagnosed by ornithine-δ-aminotransferase gene analysis: a case report."
01/01/2012 - "Deficiency of ornithine-δ-aminotransferase (OAT) in humans results in gyrate atrophy. "
04/19/2011 - "We isolated iPS cells free of transgene sequences from a patient with gyrate atrophy caused by a point mutation in the gene encoding ornithine-δ-aminotransferase (OAT) and used homologous recombination to correct the genetic defect. "
07/01/1987 - "During the 2-year interval of the study, the ornithine HCl supplements were withdrawn on 2 occasions, and within a week the hyperammonemia recurred. "
11/01/2013 - "Successful continuous venovenous hemofiltration in a neonate with hyperammonemia from ornithine transcabamylase deficiency."
06/01/2010 - "In conditional ornithine deficiency, daily supplementation with LOLA at doses about 1 g/day is safe and, as demonstrated in vitro, should be sufficient to saturate tissue ornithine concentration to prevent postprandial hyperammonemia and to stimulate tissue regeneration."
12/01/2007 - "Ornithine supplementation restored ureagenesis and mitigated hyperammonemia. "
09/01/2006 - "Although most human AI-deficient patients have no symptomatic hyperammonemia at birth, it is possible that clinically significant ornithine deficiency is already present."
02/24/1994 - "Increase of the brain uptake index for L-ornithine in rats with hepatic encephalopathy."
04/01/1993 - "These findings and the observation that administration of ornithine in combination with a branched-chain 2-oxoacid ameliorated the pathologic symptoms of portal-systemic encephalopathy suggest inhibition of OAT in the treatment of this disease. "
02/24/1994 - "We measured the brain uptake index (BUI) for radiolabelled L-ornithine (ORN) in rats with acute hepatic encephalopathy (HE) induced by two (onset stage) or three (comatous stage) administrations of a hepatotoxin-thioacetamide (TAA). "
10/01/1980 - "We conclude that the combination of ornithine and branched-chain ketoacids improves chronic portal-systemic encephalopathy more than its components given separately and more than branched-chain amino acids at twice the molar dose."
10/01/1980 - "The use of ornithine salts of branched-chain ketoacids in portal-systemic encephalopathy."
01/01/1992 - "Protective effect of NG-nitro-L-arginine (N5-[imino(nitroamino)methyl]-L-ornithine) against cyanide-induced convulsions in mice."
02/01/1986 - "High doses of arginine precipitated seizures, although plasma levels of arginine and ornithine were not altered. "
02/01/1993 - "Enhanced endogenous ornithine concentrations protect against tonic seizures and coma in acute ammonia intoxication."
01/01/1984 - "Among amino acids in CSF of children with tonic-clonic seizure, infantile spasms or Lennox syndrome, only the ornithine level was commonly lower than that of the controls. "
02/01/1993 - "However, since brain ornithine concentrations are greatly enhanced by 5FMOrn, it is not excluded that ornithine has direct effects on cellular events involved in ammonia-induced seizure generation, even though 5FMOrn had no anticonvulsant properties in a series of established animal seizure models, including N-methyl-D,L-aspartate-induced convulsions. "
11/01/1991 - "The purpose of this study was to determine if ornithine could ameliorate the thrombocytopenia of higher DFMO doses and increase the efficacy of DFMO. "
11/01/1991 - "Concomitant ornithine administration (at selected molar ratios to DFMO) ameliorated thrombocytopenia induced by DFMO at a dose of 2000 mg/kg/day without adversely affecting its antitumor activity. "
08/01/1989 - "These results suggest that ornithine can selectively inhibit DFMO-induced thrombocytopenia while not affecting the antitumor activity."
01/01/1998 - "We have demonstrated that DFMO-induced thrombocytopenia can be ameliorated with concomitant ornithine (Orn) in chow-fed rats; a reversal in DFMO-associated tumor polyamine reduction and antitumor activity, however, was also evident. "
11/01/1991 - "Concomitant ornithine infusion overcame the thrombocytopenia that was induced by either dose of DFMO without reducing the antitumor activity against the sarcoma. "
|4.||phenylacetic acid (phenylacetate)
|5.||Glutamic Acid (Glutamate)
|6.||gamma-Aminobutyric Acid (GABA)
|1.||Total Parenteral Nutrition